Accessibility Statement Skip Navigation
  • Resources
  • Investor Relations
  • Journalists
  • Agencies
  • Client Login
  • Send a Release
Return to PR Newswire homepage
  • News
  • Products
  • Contact
Search
When typing in this field, a list of search results will appear and be automatically updated as you type.

Searching for your content...

No results found. Please change your search terms and try again.
  • News Releases view all

    • News in Focus
        • Browse News Releases

        • All News Releases
        • All Public Company
        • English-only
        • News Releases Overview

        • Multimedia Gallery

        • All Multimedia
        • All Photos
        • All Videos
        • Multimedia Gallery Overview

        • Trending Topics

        • All Trending Topics
    • Business & Money
        • Auto & Transportation

        • Aerospace, Defense
        • Air Freight
        • Airlines & Aviation
        • Automotive
        • Maritime & Shipbuilding
        • Railroads and Intermodal Transportation
        • Supply Chain/Logistics
        • Transportation, Trucking & Railroad
        • Travel
        • Trucking and Road Transportation
        • Auto & Transportation Overview

        • View All Auto & Transportation

        • Business Technology

        • Blockchain
        • Broadcast Tech
        • Computer & Electronics
        • Computer Hardware
        • Computer Software
        • Data Analytics
        • Electronic Commerce
        • Electronic Components
        • Electronic Design Automation
        • Financial Technology
        • High Tech Security
        • Internet Technology
        • Nanotechnology
        • Networks
        • Peripherals
        • Semiconductors
        • Business Technology Overview

        • View All Business Technology

        • Entertain­ment & Media

        • Advertising
        • Art
        • Books
        • Entertainment
        • Film and Motion Picture
        • Magazines
        • Music
        • Publishing & Information Services
        • Radio & Podcast
        • Television
        • Entertainment & Media Overview

        • View All Entertain­ment & Media

        • Financial Services & Investing

        • Accounting News & Issues
        • Acquisitions, Mergers and Takeovers
        • Banking & Financial Services
        • Bankruptcy
        • Bond & Stock Ratings
        • Conference Call Announcements
        • Contracts
        • Cryptocurrency
        • Dividends
        • Earnings
        • Earnings Forecasts & Projections
        • Financing Agreements
        • Insurance
        • Investments Opinions
        • Joint Ventures
        • Mutual Funds
        • Private Placement
        • Real Estate
        • Restructuring & Recapitalization
        • Sales Reports
        • Shareholder Activism
        • Shareholder Meetings
        • Stock Offering
        • Stock Split
        • Venture Capital
        • Financial Services & Investing Overview

        • View All Financial Services & Investing

        • General Business

        • Awards
        • Commercial Real Estate
        • Corporate Expansion
        • Earnings
        • Environmental, Social and Governance (ESG)
        • Human Resource & Workforce Management
        • Licensing
        • New Products & Services
        • Obituaries
        • Outsourcing Businesses
        • Overseas Real Estate (non-US)
        • Personnel Announcements
        • Real Estate Transactions
        • Residential Real Estate
        • Small Business Services
        • Socially Responsible Investing
        • Surveys, Polls and Research
        • Trade Show News
        • General Business Overview

        • View All General Business

    • Science & Tech
        • Consumer Technology

        • Artificial Intelligence
        • Blockchain
        • Cloud Computing/Internet of Things
        • Computer Electronics
        • Computer Hardware
        • Computer Software
        • Consumer Electronics
        • Cryptocurrency
        • Data Analytics
        • Electronic Commerce
        • Electronic Gaming
        • Financial Technology
        • Mobile Entertainment
        • Multimedia & Internet
        • Peripherals
        • Social Media
        • STEM (Science, Tech, Engineering, Math)
        • Supply Chain/Logistics
        • Wireless Communications
        • Consumer Technology Overview

        • View All Consumer Technology

        • Energy & Natural Resources

        • Alternative Energies
        • Chemical
        • Electrical Utilities
        • Gas
        • General Manufacturing
        • Mining
        • Mining & Metals
        • Oil & Energy
        • Oil and Gas Discoveries
        • Utilities
        • Water Utilities
        • Energy & Natural Resources Overview

        • View All Energy & Natural Resources

        • Environ­ment

        • Conservation & Recycling
        • Environmental Issues
        • Environmental Policy
        • Environmental Products & Services
        • Green Technology
        • Natural Disasters
        • Environment Overview

        • View All Environ­ment

        • Heavy Industry & Manufacturing

        • Aerospace & Defense
        • Agriculture
        • Chemical
        • Construction & Building
        • General Manufacturing
        • HVAC (Heating, Ventilation and Air-Conditioning)
        • Machinery
        • Machine Tools, Metalworking and Metallurgy
        • Mining
        • Mining & Metals
        • Paper, Forest Products & Containers
        • Precious Metals
        • Textiles
        • Tobacco
        • Heavy Industry & Manufacturing Overview

        • View All Heavy Industry & Manufacturing

        • Telecomm­unications

        • Carriers and Services
        • Mobile Entertainment
        • Networks
        • Peripherals
        • Telecommunications Equipment
        • Telecommunications Industry
        • VoIP (Voice over Internet Protocol)
        • Wireless Communications
        • Telecommunications Overview

        • View All Telecomm­unications

    • Lifestyle & Health
        • Consumer Products & Retail

        • Animals & Pets
        • Beers, Wines and Spirits
        • Beverages
        • Bridal Services
        • Cannabis
        • Cosmetics and Personal Care
        • Fashion
        • Food & Beverages
        • Furniture and Furnishings
        • Home Improvement
        • Household, Consumer & Cosmetics
        • Household Products
        • Jewelry
        • Non-Alcoholic Beverages
        • Office Products
        • Organic Food
        • Product Recalls
        • Restaurants
        • Retail
        • Supermarkets
        • Toys
        • Consumer Products & Retail Overview

        • View All Consumer Products & Retail

        • Entertain­ment & Media

        • Advertising
        • Art
        • Books
        • Entertainment
        • Film and Motion Picture
        • Magazines
        • Music
        • Publishing & Information Services
        • Radio & Podcast
        • Television
        • Entertainment & Media Overview

        • View All Entertain­ment & Media

        • Health

        • Biometrics
        • Biotechnology
        • Clinical Trials & Medical Discoveries
        • Dentistry
        • FDA Approval
        • Fitness/Wellness
        • Health Care & Hospitals
        • Health Insurance
        • Infection Control
        • International Medical Approval
        • Medical Equipment
        • Medical Pharmaceuticals
        • Mental Health
        • Pharmaceuticals
        • Supplementary Medicine
        • Health Overview

        • View All Health

        • Sports

        • General Sports
        • Outdoors, Camping & Hiking
        • Sporting Events
        • Sports Equipment & Accessories
        • Sports Overview

        • View All Sports

        • Travel

        • Amusement Parks and Tourist Attractions
        • Gambling & Casinos
        • Hotels and Resorts
        • Leisure & Tourism
        • Outdoors, Camping & Hiking
        • Passenger Aviation
        • Travel Industry
        • Travel Overview

        • View All Travel

    • Policy & Public Interest
        • Policy & Public Interest

        • Advocacy Group Opinion
        • Animal Welfare
        • Congressional & Presidential Campaigns
        • Corporate Social Responsibility
        • Domestic Policy
        • Economic News, Trends, Analysis
        • Education
        • Environmental
        • European Government
        • FDA Approval
        • Federal and State Legislation
        • Federal Executive Branch & Agency
        • Foreign Policy & International Affairs
        • Homeland Security
        • Labor & Union
        • Legal Issues
        • Natural Disasters
        • Not For Profit
        • Patent Law
        • Public Safety
        • Trade Policy
        • U.S. State Policy
        • Policy & Public Interest Overview

        • View All Policy & Public Interest

    • People & Culture
        • People & Culture

        • Aboriginal, First Nations & Native American
        • African American
        • Asian American
        • Children
        • Diversity, Equity & Inclusion
        • Hispanic
        • Lesbian, Gay & Bisexual
        • Men's Interest
        • People with Disabilities
        • Religion
        • Senior Citizens
        • Veterans
        • Women
        • People & Culture Overview

        • View All People & Culture

    • Explore Our Platform
    • Plan Campaigns
    • Create with AI
    • Distribute Press Releases
    • Report Results
    • Amplify Content
    • All Products
    • General Inquiries
    • Editorial Bureaus
    • Partnerships
    • Media Inquiries
    • Worldwide Offices
    • Hamburger menu
    • PR Newswire: news distribution, targeting and monitoring
    • Send a Release
      • ALL CONTACT INFO
      • Contact Us

        888-776-0942
        from 8 AM - 10 PM ET

    • Searching for your content...

      No results found. Please change your search terms and try again.

      News Releases

      view all
      Close menu
    • News
    • Products
    • Contact
      • Send a Release
      • Client Login
      • Resources
      • Blog
      • Journalists
      • RSS
      • 3 News in Focus
      • 5 Business & Money
      • 5 Science & Tech
      • 5 Lifestyle & Health
      • 1 Policy & Public Interest
      • 1 People & Culture
      • Send a Release
      • Client Login
      • Resources
      • Blog
      • Journalists
      • RSS
      • Explore Our Platform
      • Plan Campaigns
      • Create with AI
      • Distribute Press Releases
      • Report Results
      • Amplify Content
      • All Products
      • Send a Release
      • Client Login
      • Resources
      • Blog
      • Journalists
      • RSS
      • General Inquiries
      • Editorial Bureaus
      • Partnerships
      • Media Inquiries
      • Worldwide Offices
      • Send a Release
      • Client Login
      • Resources
      • Blog
      • Journalists
      • RSS
      Close submenu (News in Focus) News in Focus
      • Browse News Releases
      • Multimedia Gallery
      • Trending Topics
      Close submenu (Business & Money) Business & Money
      • Auto & Transportation
      • Business Technology
      • Entertain­ment & Media
      • Financial Services & Investing
      • General Business
      Close submenu (Science & Tech) Science & Tech
      • Consumer Technology
      • Energy & Natural Resources
      • Environ­ment
      • Heavy Industry & Manufacturing
      • Telecomm­unications
      Close submenu (Lifestyle & Health) Lifestyle & Health
      • Consumer Products & Retail
      • Entertain­ment & Media
      • Health
      • Sports
      • Travel
      Close submenu (Policy & Public Interest) Policy & Public Interest
      • Policy & Public Interest
      Close submenu (People & Culture) People & Culture
      • People & Culture

      Azenta Reports Results of Third Quarter of Fiscal 2023, Ended June 30, 2023

      Azenta logo (PRNewsfoto/Azenta)

      News provided by

      Azenta

      Aug 08, 2023, 16:05 ET

      Share this article

      Share this article


      BURLINGTON, Mass., Aug. 8, 2023 /PRNewswire/ -- Azenta, Inc. (Nasdaq: AZTA) today reported financial results for the third quarter ended June 30, 2023.





















      Quarter Ended

      Dollars in millions, except per share data



      June 30, 


      March 31,


      June 30, 


      Change




      2023


      2023


      2022


      Prior Qtr


      Prior Yr.

      Revenue from Continuing Operations



      $

      166


      $

      148


      $

      133


      12

      %


      25

      %

         Organic growth















      2

      %

      Life Sciences Products



      $

      75


      $

      59


      $

      47


      27

      %


      57

      %

      Life Sciences Services



      $

      91


      $

      90


      $

      85


      2

      %


      7

      %


















      Diluted EPS Continuing Operations



      $

      (0.04)


      $

      (0.03)


      $

      (0.09)


      (35)

      %


      59

      %

      Diluted EPS Total



      $

      (0.02)


      $

      (0.07)


      $

      (0.13)


      67

      %


      82

      %


















      Non-GAAP Diluted EPS Continuing Operations



      $

      0.13


      $

      (0.06)


      $

      0.12


      nm



      12

      %

      Adjusted EBITDA Continuing Operations



      $

      13


      $

      (2)


      $

      14


      nm



      (7)

      %

      Management Comments 

      "Our third quarter results reflect positive momentum in both organic revenue growth and profitability. Our go-to-market initiatives continue to gain traction while our cost reduction efforts are providing additional support to the bottom line," stated Steve Schwartz, President and CEO. "Notably, the leverage in the business model is evident again and we generated positive free cash flow in the quarter. We are encouraged by the progress in the business over the past quarter, and while macroeconomic factors remain challenging, we are confident in the unique value we bring to our customer partnerships across pharmaceutical, biotech, and academic institutions." 

      Third Quarter Fiscal 2023 Results

      • Revenue was $166 million, up 25% year over year and 12% sequentially. Organic revenue increased 2% year over year, which excludes the impacts from foreign exchange headwinds of less than 1 percent and the contribution from acquisitions of 24 percentage points. Excluding the Consumables and Instruments ("C&I") business, which declined 27% and remains soft reflecting continued oversupply in the consumables market, the total business grew 8% year over year on an organic basis.
      • Life Sciences Products revenue was $75 million, up 57% year over year. 
        • Revenue from businesses acquired during the past year was $32 million in the quarter, including $27 million from B Medical. 
        • Organic revenue, which excludes the revenue from acquired businesses and impacts from foreign exchange headwinds, declined 9% driven by the softness in C&I.  Excluding the C&I business, organic revenue grew 10% year over year driven by a record quarter in large automated store systems.
      • Life Sciences Services revenue was $91 million, up 7% year over year.
        • Organic revenue, which excludes the foreign exchange headwinds, grew 8% year over year.
        • Sample Repository Solutions grew 6% year over year on an organic basis, driven by growth in core storage services. Genomics services organic revenue grew 8% year over year, led by strength in Next Generation Sequencing and Gene Synthesis. 

      Summary of GAAP Earnings Results

      • Operating loss was $16 million. Gross margin was 41.0%, down 3.9 points year over year, primarily due to increased amortization and purchase accounting adjustments related to acquisitions. Operating expense was $84 million, up $19 million year over year.
      • Other income included $11 million of net interest income versus $5 million in the prior year period.
      • Diluted EPS from continuing operations was ($0.04) compared to ($0.09) in the third quarter of fiscal 2022. Diluted EPS from discontinued operations was $0.02. Total diluted EPS was ($0.02), compared to ($0.13) one year ago. 

      Summary of Non-GAAP Earnings Results

      • Operating loss was $1 million. Operating margin declined 4.0 points year over year.
        • Gross margin was 45.6%, down 0.7 points year over year, reflecting flat margin in Products and lower margin in Services.
        • Operating expense in the quarter was $77 million, up $20 million year over year driven significantly by additional operating structure of businesses acquired during the past year, as well as investment in sales and research and development, net of cost reduction actions. 
      • Adjusted EBITDA was $13 million, and Adjusted EBITDA margin was 7.8%, down 2.6 points year over year.
      • Diluted EPS was $0.13, compared to $0.12 one year ago.  

      Cash and Liquidity

      • The Company ended the quarter with a total balance of cash, cash equivalents, restricted cash and marketable securities of $1.3 billion. 
      • Operating cash flow was $17 million in the quarter. Capital expenditures were $8 million. Free cash flow was $9 million. 

      Share Repurchase Program Update

      • On April 3, 2023 the Company completed its previously announced accelerated share repurchase ("ASR") program and on April 5, 2023 received final settlement of 4 million shares for a total of 10 million shares repurchased under the $500 million ASR program. During the quarter, the Company repurchased 4 million additional shares for $172 million under a 10b5-1 program. 
      • Subsequent to June 30, 2023 and as of August 8, 2023, the Company repurchased 2 million shares for $92 million under a 10b5-1 program.
      • As of August 8, 2023, fiscal year to date, the Company has repurchased a total of 16 million shares for $764 million and is on track to repurchase a total of $1 billion by the end of calendar year 2023.

      Guidance for Fourth Quarter Fiscal 2023

      The Company announced revenue and earnings guidance for the fourth quarter of fiscal 2023.  Total revenue is expected to be in the range of $155 to $173 million. Life Sciences Services revenue is expected to be in the range of $86 to $94 million. Life Sciences Products revenue excluding B Medical is expected to be in the range of $45 to $55 million. B Medical revenue is expected to be approximately $24 million. 

      Non-GAAP diluted earnings per share is expected to be in the range of ($0.02) to $0.06. GAAP diluted earnings per share from continuing operations is expected to be in the range of ($0.20) to ($0.12). 

      For the full year, the Company is narrowing its expectation for revenue to be in the range of $648 to $665 million, consistent with growth of approximately 17% to 20% year over year.  

      Conference Call and Webcast

      Azenta management will webcast its third quarter fiscal 2023 earnings conference call today at 4:30 p.m. Eastern Time. During the call, Company management will respond to questions concerning, but not limited to, the Company's financial performance, business conditions and industry outlook. Management's responses could contain information that has not been previously disclosed. 

      The call will be broadcast live over the Internet and, together with presentation materials referenced on the call, will be hosted at the Investor Relations section of Azenta's website at https://investors.azenta.com/events and will be archived online on this website for convenient on-demand replay. In addition, you may call 800- 954-0585 (US & Canada only) or +1-212-231-2927 for international callers to listen to the live webcast.

      Regulation G – Use of Non-GAAP financial Measures

      The Company supplements its GAAP financial measures with certain non-GAAP financial measures to provide investors a better perspective on the results of business operations, which the Company believes is more comparable to the similar analyses provided by its peers. These measures are not presented in accordance with, nor are they a substitute for, U.S. generally accepted accounting principles, or GAAP. These measures should always be considered in conjunction with appropriate GAAP measures. A reconciliation of non-GAAP measures to the most nearly comparable GAAP measures is included at the end of this release following the consolidated balance sheets, statements of operations and statements of cash flows.

      "Safe Harbor Statement" under Section 21E of the Securities Exchange Act of 1934

      Some statements in this release are forward-looking statements made under Section 21E of the Securities Exchange Act of 1934. These statements are neither promises nor guarantees but involve risks and uncertainties, both known and unknown, that could cause Azenta's financial and business results to differ materially from our expectations. They are based on the facts known to management at the time they are made. Other forward-looking statements include but are not limited to statements about our revenue and earnings expectations, our ability to realize margin improvement from cost reductions, and our ability to deliver financial success in the future and otherwise related to future operating or financial performance and opportunities. Factors that could cause results to differ from our expectations include the following:  our ability to reduce costs effectively, the impact of the COVID-19 global pandemic on the markets we serve, including our supply chain, and on the global economy generally; the volatility of the life sciences markets the Company serves; our possible inability to meet demand for our products due to difficulties in obtaining components and materials from our suppliers in required quantities and of required quality; the inability of customers to make payments to us when due; price competition; disputes concerning intellectual property; uncertainties in global political and economic conditions; our ability to successfully invest the cash proceeds from the sale of our Semiconductor Automation business; and other factors and other risks, including those that we have described in our filings with the Securities and Exchange Commission, including but not limited to our Annual Report on Form 10-K, Current Reports on Form 8-K and our Quarterly Reports on Form 10-Q. As a result, we can provide no assurance that our future results will not be materially different from those projected. Azenta expressly disclaims any obligation or undertaking to release publicly any updates or revisions to any such statement to reflect any change in our expectations or any change in events, conditions, or circumstances on which any such statement is based. Azenta undertakes no obligation to update the information contained in this press release.

      About Azenta Life Sciences
      Azenta, Inc. (Nasdaq: AZTA) is a leading provider of life sciences solutions worldwide, enabling impactful breakthroughs and therapies to market faster. Azenta provides a full suite of reliable cold-chain sample management solutions and multiomics services across areas such as drug development, clinical research and advanced cell therapies for the industry's top pharmaceutical, biotech, academic and healthcare institutions globally.

      Azenta is headquartered in Burlington, Massachusetts, with operations in North America, Europe and Asia. For more information, please visit www.azenta.com.

      AZENTA INVESTOR CONTACTS: 

      Sara Silverman
      Head of Investor Relations & Corporate Communications
      [email protected]

      Sherry Dinsmore
      [email protected]

      AZENTA, INC.

      CONSOLIDATED STATEMENTS OF OPERATIONS

      (unaudited)

      (In thousands, except per share data)
















      Three Months Ended


      Nine Months Ended



      June 30, 


      June 30, 



      2023


      2022


      2023


      2022














      Revenue













      Products


      $

      67,296


      $

      42,688


      $

      205,011


      $

      138,006

      Services



      98,652



      90,047



      287,704



      279,925

      Total revenue



      165,948



      132,735



      492,715



      417,931

      Cost of revenue













      Products



      42,747



      24,090



      136,855



      73,565

      Services



      55,196



      49,045



      160,754



      146,897

      Total cost of revenue



      97,943



      73,135



      297,609



      220,462

      Gross profit



      68,005



      59,600



      195,106



      197,469

      Operating expenses













      Research and development



      8,968



      6,515



      25,024



      19,895

      Selling, general and administrative



      75,465



      58,133



      241,356



      186,761

      Contingent consideration - fair value adjustments



      (1,404)



      —



      (18,549)



      600

      Restructuring charges



      812



      25



      3,773



      319

      Total operating expenses



      83,841



      64,673



      251,604



      207,575

      Operating loss



      (15,836)



      (5,073)



      (56,498)



      (10,106)

      Other income (expense)













      Interest income



      11,347



      6,822



      32,406



      9,933

      Interest expense



      —



      (2,101)



      —



      (4,111)

      Loss on extinguishment of debt



      —



      —



      —



      (632)

      Other, net



      819



      630



      (704)



      (1,617)

      (Loss) income before income taxes



      (3,670)



      278



      (24,796)



      (6,533)

      Income tax (benefit) expense



      (1,207)



      7,293



      (9,107)



      (560)

      Loss from continuing operations



      (2,463)



      (7,015)



      (15,689)



      (5,973)

      Income (loss) from discontinued operations, net of tax



      993



      (2,555)



      (1,943)



      2,159,597

      Net (loss) income


      $

      (1,470)


      $

      (9,570)


      $

      (17,632)


      $

      2,153,624

      Basic and diluted net (loss) income per share:













      Loss from continuing operations


      $

      (0.04)


      $

      (0.09)


      $

      (0.23)


      $

      (0.08)

      Income (loss) from discontinued operations, net of
      tax



      0.02



      (0.03)



      (0.03)



      28.84

      Net (loss) income per share


      $

      (0.02)


      $

      (0.13)


      $

      (0.26)


      $

      28.76

      Weighted average shares used in computing net (loss)
      income per share:













      Basic and diluted



      63,432



      74,989



      68,494



      74,879

      AZENTA, INC.

      CONSOLIDATED BALANCE SHEETS

      (unaudited)

      (In thousands, except share and per share data)










      June 30, 


      September 30,



      2023


      2022








      Assets







      Current assets







      Cash and cash equivalents


      $

      733,369


      $

      658,274

      Short-term marketable securities



      390,492



      911,764

      Accounts receivable, net of allowance for expected credit losses ($8,403 and
      $5,162, respectively)



      163,019



      163,758

      Inventories



      142,102



      85,544

      Derivative asset



      984



      124,789

      Short-term restricted cash



      2,287



      382,596

      Prepaid expenses and other current assets



      78,584



      132,621

      Total current assets



      1,510,837



      2,459,346

      Property, plant and equipment, net



      210,940



      154,470

      Long-term marketable securities



      169,422



      352,020

      Long-term deferred tax assets



      599



      1,169

      Goodwill



      793,623



      513,623

      Intangible assets, net



      312,055



      178,401

      Other assets



      71,940



      57,093

      Total assets


      $

      3,069,416


      $

      3,716,122

      Liabilities and stockholders' equity







      Current liabilities







      Accounts payable


      $

      37,990


      $

      38,654

      Deferred revenue



      45,207



      39,748

      Accrued warranty and retrofit costs



      6,258



      2,890

      Accrued compensation and benefits



      33,848



      41,898

      Accrued income taxes payable



      2,571



      28,419

      Accrued expenses and other current liabilities



      77,753



      78,937

      Total current liabilities



      203,627



      230,546

      Long-term tax reserves



      1,738



      1,684

      Long-term deferred tax liabilities



      65,700



      64,555

      Long-term pension liabilities



      288



      261

      Long-term operating lease liabilities



      61,799



      49,227

      Other long-term liabilities



      12,764



      6,463

      Total liabilities



      345,916



      352,736

      Stockholders' equity







      Preferred stock, $0.01 par value - 1,000,000 shares authorized, no shares issued or
      outstanding



      —



      —

      Common stock, $0.01 par value - 125,000,000 shares authorized, 74,656,860
      shares issued and 61,194,991 shares outstanding at June 30, 2023, 88,482,125
      shares issued and 75,020,256 shares outstanding at September 30, 2022



      747



      885

      Additional paid-in capital



      1,323,215



      1,992,017

      Accumulated other comprehensive loss



      (37,145)



      (83,916)

      Treasury stock, at cost - 13,461,869 shares at June 30, 2023 and September 30,
      2022



      (200,956)



      (200,956)

      Retained earnings



      1,637,639



      1,655,356

      Total stockholders' equity



      2,723,500



      3,363,386

      Total liabilities and stockholders' equity


      $

      3,069,416


      $

      3,716,122








      AZENTA, INC.

      CONSOLIDATED STATEMENTS OF CASH FLOWS

      (unaudited)

      (In thousands)










      Nine Months Ended



      June 30, 



      2023


      2022

      Cash flows from operating activities







      Net income (loss)


      $

      (17,632)


      $

      2,153,624

      Adjustments to reconcile net income (loss) to net cash provided by operating activities:







      Depreciation and amortization



      63,443



      38,813

      Stock-based compensation



      10,091



      10,715

      Contingent consideration adjustment



      (18,549)



      —

      Amortization and accretion on marketable securities



      (6,942)



      (7,048)

      Deferred income taxes



      (25,149)



      24,207

      Loss on extinguishment of debt



      —



      632

      Purchase accounting impact on inventory



      8,737



      —

      (Gain) loss on disposals of property, plant and equipment



      37



      (100)

      Gain on divestiture, net of tax



      —



      (2,128,761)

      Fees paid stemming from divestiture



      —



      (52,461)

      Taxes paid stemming from divestiture



      —



      (431,600)

      Changes in operating assets and liabilities:







      Accounts receivable



      29,028



      (16,298)

      Inventories



      (4,104)



      (61,345)

      Accounts payable



      (13,193)



      (8,320)

      Deferred revenue



      2,496



      8,580

      Accrued warranty and retrofit costs



      1,412



      (28)

      Accrued compensation and tax withholdings



      (15,830)



      13,835

      Accrued restructuring costs



      311



      (126)

      Other current assets and liabilities



      (36,578)



      (19,999)

      Net cash used in operating activities



      (22,422)



      (475,680)

      Cash flows from investing activities







      Purchases of property, plant and equipment



      (29,218)



      (59,730)

      Purchases of technology intangibles



      —



      (4,000)

      Purchases of marketable securities



      (236,194)



      (1,525,993)

      Sales and maturities of marketable securities



      951,504



      503,505

      Proceeds from divestiture, net of cash transferred



      —



      2,926,286

      Net Investment hedge settlement



      29,313



      —

      Acquisitions, net of cash acquired



      (386,508)



      —

      Net cash provided by investing activities



      328,897



      1,840,068

      Cash flows from financing activities







      Proceeds from issuance of common stock



      —



      3,461

      Principal payments on debt



      —



      (49,725)

      Common stock dividends paid



      —



      (7,494)

      Payment for contingent consideration related to acquisition



      —



      (10,400)

      Payment of finance leases



      (181)



      (355)

      Stock repurchase



      (672,116)



      —

      Withholding tax payments on net share settlements on equity awards



      (4,924)



      —

      Net cash used in financing activities



      (677,221)



      (64,513)

      Effects of exchange rate changes on cash and cash equivalents



      65,610



      (98,972)

      Net (decrease) increase in cash, cash equivalents and restricted cash



      (305,136)



      1,200,903

      Cash, cash equivalents and restricted cash, beginning of period



      1,041,296



      285,333

      Cash, cash equivalents and restricted cash, end of period


      $

      736,160


      $

      1,486,236

      Supplemental disclosures:







      Cash paid for income taxes, net



      41,064



      452,461

      Reconciliation of cash, cash equivalents, and restricted cash to the condensed consolidated balance sheets










      June 30, 



      September 30, 




      2023



      2022

      Cash and cash equivalents of continuing operations


      $

      733,369


      $

      658,274

      Short-term restricted cash



      2,287



      382,596

      Long-term restricted cash included in other assets



      504



      426

      Total cash, cash equivalents and restricted cash shown in the condensed consolidated statements of
      cash flows


      $

      736,160


      $

      1,041,296

      Notes on Non-GAAP Financial Measures

      Non-GAAP financial measures are used in addition to and in conjunction with results presented in accordance with GAAP and should not be relied upon to the exclusion of GAAP financial measures. Management adjusts the GAAP results for the impact of amortization of intangible assets, restructuring charges, purchase price accounting adjustments and charges related to M&A to provide investors better perspective on the results of operations which the Company believes is more comparable to the similar analysis provided by its peers.  Management also excludes special charges and gains, such as impairment losses, gains and losses from the sale of assets, certain tax benefits and charges, as well as other gains and charges that are not representative of the normal operations of the business. Management strongly encourages investors to review our financial statements and publicly filed reports in their entirety and not rely on any single measure.






















      Quarter Ended



      June 30, 2023


      March 31, 2023


      June 30, 2022





      per diluted




      per diluted




      per diluted

      Dollars in thousands, except per share
      data
          


      $


      share


      $


      share


      $


      share

      Net loss from continuing operations


      $

      (2,463)


      $

      (0.04)


      $

      (1,991)


      $

      (0.03)


      $

      (7,015)


      $

      (0.09)

      Adjustments:



















      Amortization of completed technology



      4,656



      0.07



      4,901



      0.07



      1,810



      0.02

      Purchase accounting impact on
      inventory



      2,956



      0.05



      2,912



      0.04



      —



      —

      Amortization of intangible assets



      7,522



      0.12



      7,509



      0.11



      5,747



      0.08

      Rebranding and transformation costs



      21



      —



      10



      0.00



      289



      0.00

      Restructuring related charges



      812



      0.01



      1,499



      0.02



      23



      0.00

      Contingent consideration - fair value
      adjustments



      (1,404)



      (0.02)



      (17,145)



      (0.25)



      —



      —

      Merger and acquisition costs and costs
      related to share repurchase



      219



      —



      19



      0.00



      1,662



      0.02

      Tax adjustments (1)



      (31)



      —



      56



      0.00



      8,417



      0.11

      Tax effect of adjustments 



      (3,947)



      (0.06)



      (1,934)



      (0.03)



      (2,143)



      (0.03)

      Non-GAAP adjusted net income (loss)
      from continuing operations


      $

      8,341


      $

      0.13


      $

      (4,164)


      $

      (0.06)


      $

      8,790


      $

      0.12

         Stock based compensation, pre-tax



      3,995



      0.06



      3,991



      0.06



      3,485



      0.05

         Tax rate



      15

      %


      —



      15

      %


      —



      15

      %


      —

      Stock-based compensation, net of tax



      3,396



      0.05



      3,392



      0.05



      2,962



      0.04

      Non-GAAP adjusted net income (loss)
      excluding stock-based compensation -
      continuing operations


      $

      11,737


      $

      0.18


      $

      (772)


      $

      (0.01)


      $

      11,752


      $

      0.16




















      Shares used in computing non-GAAP
      diluted net income (loss) per share



      —



      63,432



      —



      69,111



      —



      74,989
















      Nine Months Ended



      June 30, 2023


      June 30, 2022





      per diluted




      per diluted

      Dollars in thousands, except per share data    


      $


      share


      $


      share

      Net loss from continuing operations


      $

      (15,689)


      $

      (0.23)


      $

      (5,973)


      $

      (0.08)

      Adjustments:













      Amortization of completed technology



      13,725



      0.20



      5,424



      0.07

      Purchase accounting impact on inventory



      8,737



      0.13



      —



      —

      Amortization of intangible assets



      22,403



      0.33



      18,064



      0.24

      Rebranding and transformation costs



      (34)



      (0.00)



      2,205



      0.03

      Restructuring related charges



      3,773



      0.06



      319



      0.00

      Contingent consideration - fair value adjustments



      (18,549)



      (0.27)



      —



      —

      Tariff adjustment



      —



      —



      (484)



      (0.01)

      Merger and acquisition costs and costs related to
      share repurchase



      12,075



      0.18



      10,970



      0.15

      Indemnification asset release



      (19)



      (0.00)



      —



      —

      Loss on extinguishment of debt



      —



      —



      632



      0.01

      Tax adjustments (1)



      (1,411)



      (0.02)



      3,619



      0.05

      Tax effect of adjustments



      (11,881)



      (0.17)



      (8,329)



      (0.11)

      Non-GAAP adjusted net income from continuing
      operations


      $

      13,130


      $

      0.19


      $

      26,447


      $

      0.35

      Stock-based compensation, pre-tax



      10,091



      0.15



      12,492



      0.17

      Tax rate



      15

      %


      —



      15

      %


      —

      Stock-based compensation, net of tax



      8,577


      $

      0.13



      10,618



      0.14

      Non-GAAP adjusted net income excluding stock-
      based compensation - continuing operations


      $

      21,707


      $

      0.32


      $

      37,065


      $

      0.49














      Shares used in computing non-GAAP diluted net
      income per share



      —



      68,494



      —



      74,879



      (1)

      Tax adjustments during all periods include adjustments to tax benefits related to stock compensation. These adjustments are recognized in the period of vesting for US GAAP but included in the annual effective tax rate for Non-GAAP reporting. Tax adjustments for the nine months ended June 30, 2023, included a $1.3M increase to expense related to the exclusion of a benefit from an incentive tax rate change in China. Tax adjustments for the quarter ended June 30, 2022, include a $1.9M increase to expense related to the exclusion of allocations between continuing operations and discontinued operations.



















      Quarter Ended


      Nine Months Ended



      June 30, 


      March 31,


      June 30, 


      June 30, 


      June 30, 

      Dollars in thousands


      2023


      2023


      2022


      2023


      2022

      GAAP net income (loss)


      $

      (1,470)


      $

      (4,927)


      $

      (9,570)


      $

      (17,632)


      $

      2,153,624

      Less: Income (loss) from discontinued
      operations



      993



      (2,936)



      (2,555)



      (1,943)



      2,159,597

      GAAP net loss from continuing operations



      (2,463)



      (1,991)



      (7,015)



      (15,689)



      (5,973)

      Adjustments:
















      Less: Interest income



      (11,347)



      (10,394)



      (6,822)



      (32,406)



      (9,933)

      Add: Interest expense



      —



      —



      2,101



      —



      4,111

      Add / Less: Income tax provision (benefit)



      (1,207)



      (3,260)



      7,293



      (9,107)



      (560)

      Add: Depreciation



      9,126



      9,549



      5,253



      27,315



      15,777

      Add: Amortization of completed technology



      4,656



      4,901



      1,810



      13,725



      5,424

      Add: Amortization of intangible assets



      7,522



      7,509



      5,745



      22,403



      18,064

      Add: Loss on extinguishment of debt



      —



      —



      —



      —



      632

      Earnings before interest, taxes, depreciation
      and amortization - Continuing operations


      $

      6,287


      $

      6,315


      $

      8,365


      $

      6,241


      $

      27,542



















      Quarter Ended


      Nine Months Ended



      June 30, 


      March 31,


      June 30, 


      June 30, 


      June 30, 

      Dollars in thousands


      2023


      2023


      2022


      2023


      2022

      Earnings before interest, taxes, depreciation
      and amortization - Continuing operations


      $

      6,287


      $

      6,315


      $

      8,365


      $

      6,241


      $

      27,542

      Adjustments:
















      Add: Stock-based compensation



      3,995



      3,991



      3,485



      10,212



      12,492

      Add: Purchase accounting impact on
      inventory



      2,956



      2,912



      —



      8,737



      —

      Add: Restructuring related charges



      812



      1,499



      23



      3,773



      319

      Add: Merger and acquisition costs and costs
      related to share repurchase



      219



      19



      1,664



      12,075



      10,970

      Less: Contingent consideration - fair value
      adjustments



      (1,404)



      (17,145)



      —



      (18,549)



      —

      Less: Tariff adjustment



      —



      —



      —



      —



      (484)

      Less: Rebranding and transformation costs



      21



      10



      289



      (34)



      2,205

      Less: Indemnification asset release



      —



      —



      —



      (19)



      —

      Adjusted earnings before interest, taxes,
      depreciation and amortization - Continuing
      operations


      $

      12,886


      $

      (2,400)


      $

      13,826


      $

      22,436


      $

      53,044






















      Quarter Ended


      Dollars in thousands


      June 30, 2023



      March 31, 2023



      June 30, 2022


      GAAP gross profit


      $

      68,005


      41.0

      %


      $

      53,236


      35.9

      %


      $

      59,600


      44.9

      %

      Adjustments:



















      Amortization of completed technology



      4,656


      2.8




      4,901


      3.3




      1,812


      1.4


      Purchase accounting impact on inventory



      2,956


      1.8




      2,912


      2.0




      —


      —


      Non-GAAP adjusted gross profit


      $

      75,617


      45.6

      %


      $

      61,049


      41.1

      %


      $

      61,412


      46.3

      %



































      Nine Months Ended


      Dollars in thousands


      June 30, 2023



      June 30, 2022


      GAAP gross profit


      $

      195,106


      39.6

      %


      $

      197,469


      47.2

      %

      Adjustments:













      Amortization of completed technology



      13,725


      2.8




      5,424


      1.3


      Purchase accounting impact on inventory



      8,737


      1.8




      —


      —


      Tariff adjustment



      —


      —




      (486)


      (0.1)


      Non-GAAP adjusted gross profit


      $

      217,568


      44.2

      %


      $

      202,407


      48.4

      %








































       Life Sciences Products


      Life Sciences Services



      Quarter Ended


      Quarter Ended



      June 30, 



      March 31,



      June 30, 



      June 30, 



      March 31,



      June 30, 


      Dollars in thousands


      2023



      2023



      2022



      2023



      2023



      2022


      GAAP gross profit


      $

      27,213


      36.5

      %


      $

      14,284


      24.3

      %


      $

      21,026


      44.4

      %


      $

      40,792


      44.6

      %


      $

      38,952


      43.5

      %


      $

      38,564


      45.2

      %

      Adjustments:





































      Amortization of
      completed technology



      3,329


      4.4




      3,569


      6.1




      251


      0.5




      1,327


      1.5




      1,333


      1.5




      1,562


      1.8


      Purchase accounting
      impact on inventory



      2,956


      4.0




      2,912


      4.9




      —


      —




      —


      —




      —


      —




      —


      —


      Non-GAAP adjusted gross
      profit


      $

      33,498


      44.9

      %


      $

      20,765


      35.3

      %


      $

      21,277


      44.9

      %


      $

      42,119


      46.1

      %


      $

      40,285


      45.0

      %


      $

      40,126


      47.0

      %




























      Life Sciences Products


      Life Sciences Services



      Nine Months Ended


      Nine Months Ended

      Dollars in thousands


      June 30, 
      2023


      June 30, 
      2022


      June 30, 
      2023


      June 30, 
      2022

      GAAP gross profit


      $

      74,477


      33.4

      %


      $

      70,006


      46.4

      %


      $

      120,629


      44.7

      %


      $

      127,466


      47.7

      %

      Adjustments:

























      Amortization of completed
      technology



      9,743


      4.4




      722


      0.5




      3,982


      1.5




      4,702


      1.8


      Purchase accounting impact on
      inventory



      8,737


      3.9




      —


      —




      —


      —




      —


      —


      Tariff adjustment



      —


      —




      —


      —




      —


      —




      (484)


      (0.2)


      Other adjustment



      —


      —




      —


      —




      —


      —




      —


      —


      Non-GAAP adjusted gross profit


      $

      92,957


      41.7

      %


      $

      70,728


      46.9

      %


      $

      124,611


      46.2

      %


      $

      131,684


      49.3

      %















































       Life Sciences Products


      Life Sciences Services



      Quarter Ended


      Quarter Ended



      June 30, 


      March 31,


      June 30, 


      June 30, 


      March 31,


      June 30, 

      Dollars in thousands


      2023


      2023


      2022


      2023


      2023


      2022

      GAAP operating (loss) profit


      $

      (4,878)


      $

      (16,402)


      $

      1,965


      $

      (3,813)


      $

      (4,877)


      $

      688

      Adjustments:



















      Amortization of completed technology



      3,329



      3,569



      251



      1,327



      1,333



      1,562

      Purchase accounting impact on inventory



      2,956



      2,912



      —



      —



      —



      —

      Restructuring related charges



      —



      —



      —



      —



      110



      —

      Other adjustment



      —



      102



      —



      —



      —



      —

      Non-GAAP adjusted operating profit (loss)


      $

      1,407


      $

      (9,819)


      $

      2,216


      $

      (2,486)


      $

      (3,434)


      $

      2,250































      Total Segments


      Corporate


      Total



      Quarter Ended


      Quarter Ended


      Quarter Ended



      June 30, 


      March 31,


      June 30, 


      June 30, 


      March 31,


      June 30, 


      June 30, 


      March 31,


      June 30, 

      Dollars in thousands


      2023


      2023


      2022


      2023


      2023


      2022


      2023


      2023


      2022

      GAAP operating (loss) profit


      $

      (8,691)


      $

      (21,279)


      $

      2,653


      $

      (7,145)


      $

      8,302


      $

      (7,726)


      $

      (15,836)


      $

      (12,977)


      $

      (5,073)

      Adjustments:




























      Amortization of completed technology



      4,656



      4,901



      1,813



      —



      —



      —



      4,656



      4,901



      1,813

      Purchase accounting impact on inventory



      2,956



      2,912



      —



      —



      —



      —



      2,956



      2,912



      —

      Amortization of intangible assets



      —



      102



      —



      7,522



      7,407



      5,745



      7,522



      7,509



      5,745

      Rebranding and transformation costs



      —



      —



      —



      21



      10



      289



      21



      10



      289

      Restructuring related charges



      —



      110



      —



      812



      1,389



      25



      812



      1,499



      25

      Contingent consideration adjustment



      —



      —



      —



      (1,404)



      (17,145)



      —



      (1,404)



      (17,145)



      —

      Merger and acquisition costs and costs
      related to share repurchase



      —



      —



      —



      219



      (211)



      1,662



      219



      (211)



      1,662

      Other adjustment



      —



      —



      —



      (2)



      230



      —



      (2)



      230



      —

      Non-GAAP adjusted operating (loss) profit


      $

      (1,079)


      $

      (13,254)


      $

      4,466


      $

      23


      $

      (18)


      $

      (5)


      $

      (1,056)


      $

      (13,272)


      $

      4,461
















      Life Sciences Products


      Life Sciences Services



      Nine Months Ended


      Nine Months Ended

      Dollars in thousands


      June 30, 


      June 30, 


      June 30, 


      June 30, 



      2023


      2022


      2023


      2022

      GAAP operating (loss) profit


      $

      (25,077)


      $

      11,173


      $

      (13,302)


      $

      10,772

      Adjustments:













      Amortization of completed technology



      9,743



      722



      3,982



      4,702

      Purchase accounting impact on inventory



      8,737



      —



      —



      —

      Tariff adjustment



      —



      —



      —



      (484)

      Other adjustment



      1,515



      —



      110




      Non-GAAP adjusted operating (loss) profit


      $

      (5,082)


      $

      11,895


      $

      (9,210)


      $

      14,990






















      Total Segments


      Corporate


      Total



      Nine Months Ended


      Nine Months Ended


      Nine Months Ended

      Dollars in thousands


      June 30, 


      June 30, 


      June 30, 


      June 30, 


      June 30, 


      June 30, 



      2023


      2022


      2023


      2022


      2023


      2022

      GAAP operating (loss) profit


      $

      (38,379)


      $

      21,945


      $

      (18,119)


      $

      (32,052)


      $

      (56,498)


      $

      (10,107)

      Adjustments:



















      Amortization of completed technology



      13,725



      5,424



      —



      —



      13,725



      5,424

      Purchase accounting impact on inventory



      8,737



      —



      —



      —



      8,737



      —

      Amortization of other intangibles



      —



      —



      22,403



      18,064



      22,403



      18,064

      Rebranding and transformation costs



      —



      —



      (34)



      2,205



      (34)



      2,205

      Restructuring related charges



      —



      —



      3,773



      319



      3,773



      319

      Contingent consideration - fair value adjustments



      —



      —



      (18,549)



      —



      (18,549)



      —

      Tariff adjustment



      —



      (484)



      —



      —



      —



      (484)

      Merger and acquisition costs and costs related to
      share repurchase



      —



      —



      12,075



      10,970



      12,075



      10,970

      Other adjustment



      1,625



      —



      (1,625)



      —



      —



      —

      Non-GAAP adjusted operating (loss) profit


      $

      (14,292)


      $

      26,885


      $

      (76)


      $

      (494)


      $

      (14,368)


      $

      26,391































      Life Sciences Products


      Life Sciences Services


      Azenta Total



      Quarter Ended


      Quarter Ended


      Quarter Ended



      June 30, 


      June 30, 





      June 30, 


      June 30, 





      June 30, 


      June 30, 




      Dollars in millions


      2023



      2022


      Change


      2023


      2022


      Change


      2023


      2022


      Change

       Revenue


      $

      75


      $

      47


      57

      %


      $

      91


      $

      85


      7

      %


      $

      166


      $

      133


      25

      %

      Acquisitions/divestitures



      32



      —


      (67)

      %



      —



      —


      0

      %



      32



      —


      (24)

      %

      Currency exchange rates



      (0)



      —


      0

      %



      (0)



      —


      1

      %



      (1)



      —


      0

      %

      Organic revenue



      43



      47


      (9)

      %



      92



      85


      8

      %



      135



      133


      2

      %

      SOURCE Azenta

      Modal title

      Also from this source

      Azenta to Participate in the 9th Annual Evercore Healthcare Conference

      Azenta to Participate in the 9th Annual Evercore Healthcare Conference

      Azenta, Inc. (Nasdaq: AZTA) today announced that Company management will participate in the 9th Annual Evercore Healthcare Conference on Monday,...

      Azenta Reports Fourth Quarter and Full Year Results for Fiscal 2026, Ended September 30, 2026.

      Azenta Reports Fourth Quarter and Full Year Results for Fiscal 2026, Ended September 30, 2026.

      Azenta, Inc. (Nasdaq: AZTA) today reported financial results for the fourth quarter and fiscal year ended September 30, 2026. B Medical Systems is...

      More Releases From This Source

      Explore

      Health Care & Hospitals

      Health Care & Hospitals

      Medical Pharmaceuticals

      Medical Pharmaceuticals

      Earnings

      Earnings

      Earnings Forecasts & Projections

      Earnings Forecasts & Projections

      News Releases in Similar Topics

      Contact PR Newswire

      • Call PR Newswire at 888-776-0942
        from 8 AM - 9 PM ET
      • Chat with an Expert
      • General Inquiries
      • Editorial Bureaus
      • Partnerships
      • Media Inquiries
      • Worldwide Offices

      Products

      • Explore Our Platform
      • Plan Campaigns
      • Create with AI
      • Distribute Press Releases
      • Report Results
      • Amplify Content

      About

      • About PR Newswire
      • About Cision
      • Careers
      • Accessibility Statement
      • APAC
      • APAC - Simplified Chinese
      • APAC - Traditional Chinese
      • Brazil
      • Canada
      • Czech
      • Denmark
      • Finland
      • France
      • Germany
      • India
      • Indonesia
      • Israel
      • Italy
      • Japan
      • Korea
      • Mexico
      • Middle East
      • Middle East - Arabic
      • Netherlands
      • Norway
      • Poland
      • Portugal
      • Russia
      • Slovakia
      • Spain
      • Sweden
      • United Kingdom
      • Vietnam

      My Services

      • All New Releases
      • Platform Login
      • Data Privacy

      Do not sell or share my personal information:

      • Submit via [email protected] 
      • Call Privacy toll-free: 877-297-8921

      Contact PR Newswire

      Products

      About

      My Services
      • All News Releases
      • Platform Login
      • ProfNet
      Call PR Newswire at
      888-776-0942
      • Terms of Use
      • Privacy Policy
      • Information Security Policy
      • Site Map
      • RSS
      • Cookies
      Copyright © 2026 Cision US Inc.